Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service (Process Development), By Drug Type (Biologics, Biosimilars), By Type, By Scale of Operation, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Biopharmaceuticals Contract Manufacturing Market Growth & Trends
The global biopharmaceuticals contract manufacturing market size is estimated treach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 t2030, according ta new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are twkey factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolitmeet the companies' demands with respect tregulatory standards and new services. The pandemic has, however, alshad some negative knock-on effects as budgets and resources are diverted t“COVID products” at the expense of other biologics projects in development for other therapeutic areas.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected trise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related tCOVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are twimportant opportunities that are anticipated tdrive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Biopharmaceuticals Contract Manufacturing Market Report Highlights
Biopharmaceuticals Contract Manufacturing Market Growth & Trends
The global biopharmaceuticals contract manufacturing market size is estimated treach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 t2030, according ta new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are twkey factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolitmeet the companies' demands with respect tregulatory standards and new services. The pandemic has, however, alshad some negative knock-on effects as budgets and resources are diverted t“COVID products” at the expense of other biologics projects in development for other therapeutic areas.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected trise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related tCOVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are twimportant opportunities that are anticipated tdrive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Biopharmaceuticals Contract Manufacturing Market Report Highlights
- Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing tthe high penetration of mammalian expression systems for biologics development
- Process development services held the largest revenue share in the global market in 2024., owing thigh capital investment, especially in downstream process
- Biologics contract manufacturing dominated its counterpart segment owing thigher demand for biologics production. However, The biosimilar segment is anticipated tregister the fastest CAGR over the forecast period due tcost-saving advantages associated with biosimilars development
- The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
- Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected temerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing tdeveloping economies such as India and China incorporating developments tsustain the competition
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rise in investment by CMOs for capacity expansion
3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
3.2.1.3. Notable growth of biologics approvals
3.2.1.4. Robust biopharmaceuticals pipeline
3.2.1.5. Cost and time-saving benefits offered by contract services
3.2.2. Market Restraints Analysis
3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
3.2.2.2. Managing Relationships
3.3. Product Pipeline Analysis
3.4. Pricing Model Analysis
3.5. Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
CHAPTER 4. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SOURCE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Source Movement Analysis
4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SERVICE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Service Movement Analysis
5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
5.4. Process Development
5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Downstream Processing
5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Upstream Processing
5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Fill & Finish Operations
5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Analytical & QC Studies
5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Packaging & Labelling
5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Drug Type Movement Analysis
6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
6.4. Biologics
6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Monoclonal Antibodies
6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Recombinant proteins
6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Vaccines
6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Antisense, RNAi, & Molecular Therapy
6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Biosimilar
6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: TYPE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Type Movement Analysis
7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
7.4. Drug Substance
7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Finished Drug Product
7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SCALE OF OPERATION ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Scale of Operation Movement Analysis
8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Therapeutic Area Movement Analysis
9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
9.4. Oncology
9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Autoimmune Diseases
9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Infectious Diseases
9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Cardiovascular Diseases
9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8. Metabolic Diseases
9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.9. Neurology
9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.10. Others
9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional market share analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. North America
10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.2. U.S.
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Landscape
10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Landscape
10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Landscape
10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4. Europe
10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.2. U.K.
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Landscape
10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Landscape
10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Landscape
10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Landscape
10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Landscape
10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Landscape
10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Landscape
10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Landscape
10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5. Asia Pacific
10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.2. China
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Landscape
10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.3. Japan
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Landscape
10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.4. India
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Landscape
10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.5. South Korea
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Landscape
10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.6. Australia
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Landscape
10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.7. Thailand
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Landscape
10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6. Latin America
10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Landscape
10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Landscape
10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7. Middle East and Africa
10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.2. Saudi Arabia
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Landscape
10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Landscape
10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.4. South Africa
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Landscape
10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Landscape
10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
11.3. Company Profiles
11.3.1. Boehringer Ingelheim GmbH
11.3.1.1. Participant’s Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Participant’s Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Inno Biologics Sdn Bhd
11.3.3.1. Participant’s Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Rentschler Biotechnologies GmbH
11.3.4.1. Participant’s Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. JRS PHARMA
11.3.5.1. Participant’s Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. AGC Biologics
11.3.6.1. Participant’s Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. ProBioGen
11.3.7.1. Participant’s Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
11.3.8.1. Participant’s Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Toyobo Co. Ltd.
11.3.9.1. Participant’s Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Samsung Biologics
11.3.10.1.1. Participant’s Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Thermo Fisher Scientific, Inc.
11.3.11.1. Participant’s Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Binex Co., Ltd.
11.3.12.1. Participant’s Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. WuXi Biologics
11.3.13.1. Participant’s Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. AbbVie, Inc.
11.3.14.1. Participant’s Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. ADMA Biologics, Inc.
11.3.15.1. Participant’s Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Catalent, Inc
11.3.16.1. Participant’s Overview
11.3.16.2. Financial Performance
11.3.16.3. Service Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. Cambrex Corporation
11.3.17.1. Participant’s Overview
11.3.17.2. Financial Performance
11.3.17.3. Service Benchmarking
11.3.17.4. Strategic Initiatives
11.3.18. Pfizer Inc.
11.3.18.1. Participant’s Overview
11.3.18.2. Financial Performance
11.3.18.3. Service Benchmarking
11.3.18.4. Strategic Initiatives
11.3.19. Siegfried Holding AG
11.3.19.1. Participant’s Overview
11.3.19.2. Financial Performance
11.3.19.3. Service Benchmarking
11.3.19.4. Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rise in investment by CMOs for capacity expansion
3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
3.2.1.3. Notable growth of biologics approvals
3.2.1.4. Robust biopharmaceuticals pipeline
3.2.1.5. Cost and time-saving benefits offered by contract services
3.2.2. Market Restraints Analysis
3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
3.2.2.2. Managing Relationships
3.3. Product Pipeline Analysis
3.4. Pricing Model Analysis
3.5. Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
CHAPTER 4. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SOURCE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Source Movement Analysis
4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SERVICE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Service Movement Analysis
5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
5.4. Process Development
5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Downstream Processing
5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Upstream Processing
5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Fill & Finish Operations
5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Analytical & QC Studies
5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Packaging & Labelling
5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Drug Type Movement Analysis
6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
6.4. Biologics
6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Monoclonal Antibodies
6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Recombinant proteins
6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Vaccines
6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Antisense, RNAi, & Molecular Therapy
6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Biosimilar
6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: TYPE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Type Movement Analysis
7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
7.4. Drug Substance
7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Finished Drug Product
7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: SCALE OF OPERATION ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Scale of Operation Movement Analysis
8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Therapeutic Area Movement Analysis
9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
9.4. Oncology
9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Autoimmune Diseases
9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Infectious Diseases
9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Cardiovascular Diseases
9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8. Metabolic Diseases
9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.9. Neurology
9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.10. Others
9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional market share analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. North America
10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.2. U.S.
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Landscape
10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Landscape
10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Landscape
10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4. Europe
10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.2. U.K.
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Landscape
10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Landscape
10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Landscape
10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Landscape
10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Landscape
10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Landscape
10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Landscape
10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Landscape
10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5. Asia Pacific
10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.2. China
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Landscape
10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.3. Japan
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Landscape
10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.4. India
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Landscape
10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.5. South Korea
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Landscape
10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.6. Australia
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Landscape
10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.7. Thailand
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Landscape
10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6. Latin America
10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Landscape
10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Landscape
10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7. Middle East and Africa
10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.2. Saudi Arabia
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Landscape
10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Landscape
10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.4. South Africa
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Landscape
10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Landscape
10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
11.3. Company Profiles
11.3.1. Boehringer Ingelheim GmbH
11.3.1.1. Participant’s Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Participant’s Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Inno Biologics Sdn Bhd
11.3.3.1. Participant’s Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Rentschler Biotechnologies GmbH
11.3.4.1. Participant’s Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. JRS PHARMA
11.3.5.1. Participant’s Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. AGC Biologics
11.3.6.1. Participant’s Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. ProBioGen
11.3.7.1. Participant’s Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
11.3.8.1. Participant’s Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Toyobo Co. Ltd.
11.3.9.1. Participant’s Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Samsung Biologics
11.3.10.1.1. Participant’s Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Thermo Fisher Scientific, Inc.
11.3.11.1. Participant’s Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Binex Co., Ltd.
11.3.12.1. Participant’s Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. WuXi Biologics
11.3.13.1. Participant’s Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. AbbVie, Inc.
11.3.14.1. Participant’s Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. ADMA Biologics, Inc.
11.3.15.1. Participant’s Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Catalent, Inc
11.3.16.1. Participant’s Overview
11.3.16.2. Financial Performance
11.3.16.3. Service Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. Cambrex Corporation
11.3.17.1. Participant’s Overview
11.3.17.2. Financial Performance
11.3.17.3. Service Benchmarking
11.3.17.4. Strategic Initiatives
11.3.18. Pfizer Inc.
11.3.18.1. Participant’s Overview
11.3.18.2. Financial Performance
11.3.18.3. Service Benchmarking
11.3.18.4. Strategic Initiatives
11.3.19. Siegfried Holding AG
11.3.19.1. Participant’s Overview
11.3.19.2. Financial Performance
11.3.19.3. Service Benchmarking
11.3.19.4. Strategic Initiatives
